Samsung Medical Center

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Subsidiary

Established: 1994-01-01

Employees: 501

Market Cap: -

Website: http://www.samsunghospital.com

Clinical Trials

VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)

Phase 2

Conditions: Extranodal NK-T-Cell Lymphoma

Interventions: Drug: Etoposide
Drug: Ifosfamide
Drug: Dexamethasone
Drug: L-asparaginase
Drug: Busulfan
Drug: Melphalan

First Posted Date: 2015-09-09

Last Posted Date: 2020-10-22

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 27

Registration Number: NCT02544425

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Poziotinib

First Posted Date: 2015-09-09

Last Posted Date: 2020-07-07

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 5

Registration Number: NCT02544997

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma

Phase 2

Conditions: Urothelial Carcinoma

Interventions: Drug: tipifarnib

First Posted Date: 2015-08-28

Last Posted Date: 2022-03-08

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 19

Registration Number: NCT02535650

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Trial of Proton Pump Inhibitor With Prokinetics or Placebo in Patients With Laryngopharyngeal Reflux Disease

Phase 3

Conditions: Laryngopharyngeal Reflux Disease

Interventions: Drug: Pantoprazole
Drug: Motilitone
Drug: Placebo

First Posted Date: 2015-08-26

Last Posted Date: 2016-06-01

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 200

Registration Number: NCT02533349

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

A New Track Ablation Device for Liver Biopsy: A Feasibility Study

Phase 1

Conditions: Liver Neoplasms

Interventions: Device: Biopsy Track Ablator (STARmed, Goyang, Korea)

First Posted Date: 2015-08-13

Last Posted Date: 2015-08-13

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 20

Registration Number: NCT02521129

Adjuvant Durvalumab for Esophageal Cancer

Phase 2

Conditions: Esophageal Cancer

Interventions: Drug: Durvalumab
Drug: Placebo

First Posted Date: 2015-08-11

Last Posted Date: 2019-12-09

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 86

Registration Number: NCT02520453

Locations: 🇰🇷
Samsung Medical Center, Seoul, MA, Korea, Republic of

The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease

Phase 2

Conditions: Coronary Syndrome

Interventions: Drug: Rosuvastatin
Drug: Olmesartan
Drug: Combination
Drug: Placebo of Rosuvastatin
Drug: Placebo of Rosuvastatin/Olmesartan(Combination)
Drug: Placebo of Olmesartan

First Posted Date: 2015-08-06

Last Posted Date: 2015-08-06

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 504

Registration Number: NCT02516826

Locations: 🇰🇷
Cardiac and Vascular Center; Samsung Medical Center, Seoul, Korea, Republic of

Thoracic Epidural for Postoperative Ileus

Not Applicable

Completed

Conditions: Ileus

Interventions: Drug: iv-PCA
Procedure: thoracic epidural analgesia

First Posted Date: 2015-07-08

Last Posted Date: 2015-07-08

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 28

Registration Number: NCT02491385

Locations: 🇰🇷
Samsung medical center, Seoul, Korea, Republic of

EAA/Therapy for Treating Children With ADHD

Not Applicable

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Behavioral: EAA/T
Drug: Methylphenidate
Drug: Atomoxetine

First Posted Date: 2015-06-26

Last Posted Date: 2015-06-26

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 46

Registration Number: NCT02482649

Locations: 🇰🇷
Yoo-Sook Joung, Seoul, Korea, Republic of

Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.

Phase 4

Completed

Conditions: Overactive Bladder

Interventions: Drug: mirabegron 50mg

First Posted Date: 2015-06-10

Last Posted Date: 2018-02-28

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 434

Registration Number: NCT02468375

Locations: 🇰🇷
Samsung Medical Center, Seoul,, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy